In the present study, the contribution of pharmacogenetic variability in CYP2B6 and CYP2C19 to treatment efficacy and cyclophosphamide-induced side effects was evaluated in pediatric patients with neuroblastoma. The gene discussed is CYP2B6; the disease is neuroblastoma.